Peripheral Vascular Stents Market (2026 - 2033)

Peripheral Vascular Stents Market Summary

The global peripheral vascular stents market was valued at USD 2.1 billion in 2025 and is projected to grow from USD 2.3 billion in 2026 to USD 3.7 billion in 2033, at a CAGR of 7.0% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 43.0% in 2025. The market for peripheral vascular stents is projected to witness growth driven by various factors, including the rising prevalence of peripheral diseases, a growing elderly population, and the introduction of advanced product offerings.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Diseases such as peripheral arterial disease (PAD), atherosclerosis, and deep vein thrombosis are becoming more prevalent, resulting in a substantial demand for peripheral vascular stents. According to American Heart Association, Peripheral Artery Disease (PAD) remains a major global cardiovascular health concern and is associated with an increased risk of heart attack.

According to the American Heart Association, Inc., nearly 70.0% Americans are unaware that they may be at risk of being diagnosed with peripheral artery disease. Multiple factors, such as Atherosclerosis, claudication and pain, critical limb ischemia (CLI), renal artery stenosis, aneurysms, carotid artery disease, and others, can lead to the use of peripheral stents. However, cardiology procedures are now being conducted as usual, as the pandemic has subsided. Consequently, the market for peripheral vascular stents is expected to experience stable growth during the forecast period, considering the subsiding effects of the pandemic.

To learn more about this report, Download Free Sample Report

The continuous evolution of stent design has led to enhanced stent performance and patient outcomes. Manufacturers have focused on developing stents with improved flexibility, deliverability, and radial strength, allowing for better deployment and expansion within the peripheral arteries. For instance, in May 2025, Abbott announced that its Esprit BTK Everolimus Eluting Resorbable Scaffold System received CE Mark in Europe. The product features a delivery system for everolimus drug incorporated to support vessel healing before completely dissolving. Such advancements are likely to improve procedural success rates and reduce complications associated with stent placement.

Prominent market players play a vital role in promoting the adoption of technological advancements within the peripheral vascular stent market. Major companies actively incorporate these advancements into their product offerings to enhance patient outcomes and broaden the availability of advanced treatment options. Furthermore, strategic collaborations and partnerships enable market players to access untapped market segments and expand their geographical reach, thereby driving overall growth.

The aging population has been a significant driving factor for the growing demand for peripheral vascular stents. According to the WHO, it is estimated that by the year 2030, one out of every six individuals worldwide is estimated to be 60 years or over. Moreover, by 2050, the number of people aged 60 and older is expected to reach 2.1 billion. Thus, with the aging population being more prone to peripheral vascular diseases, the demand for peripheral stents is expected to grow substantially to cater to this demographic, driving the market growth.

Analyst Perspective

The peripheral vascular stents market is poised to maintain steady growth, which is supported by increasing global burden of peripheral artery disease, continued technological advancement in stent design, and rising geriatric population. Improvements in stent flexibility, more radial strengthen, and continuous technological advancements are enhancing procedural outcomes, which encourage wider adoption of minimally invasive endovascular interventions. Additionally, innovative technologies which are aimed at reducing restenosis and vessel recoil are expanding treatment options for patients. As healthcare systems continue to normalize the following awareness regarding PAD, the demand for vascular interventions is expected to rise, which creates favorable growth opportunities for market participants.

Type Insights

Based on type, the drug-eluting stents (DES) segment accounted for the largest market share of more than 60.0% in 2025. Drug-eluting stents can reduce the rate of restenosis compared to bare metal stents (BMS). The ability of DES to reduce the incidence of major adverse cardiac events (MACE) is a significant driving factor for their widespread adoption. The drug coating on the stent prevents stent thrombosis, reducing the risk of blood clot formation within the stent. This lowers the occurrence of heart attacks, strokes, and other cardiovascular events, leading to improved patient safety and overall survival rates.

For instance, in March 2026, Abbott launched its XIENCE Skypoint in India, designed to be more flexible and easier to guide through the heart’s arteries. It incorporates a novel delivery mechanism specifically designed to enhance acute performance, particularly in challenging cases. This advancement aims to improve patient outcomes and provide better treatment options for individuals with complex conditions.T

The bioabsorbable stents segment is also expected to grow significantly over the forecast period. Bioabsorbable stents have emerged as a revolutionary advancement in interventional cardiology. It eliminates long-term risks like in-stent restenosis and late-stent thrombosis by gradually dissolving in the body, reducing the chances of adverse events. Unlike permanent stents, bioabsorbable stents allow the artery to maintain natural flexibility and movement, resulting in better patient outcomes.The need to overcome the limitations associated with permanent stents is the primary driving force behind developing and adopting bioabsorbable stents.

Mode of Delivery Insights

Based on mode of delivery, the balloon-expanding stents segment accounted for the largest share of more than 53.0% in 2025. Balloon-expanding stents offer a significant benefit by enabling accurate and controlled expansion within the affected blood vessel. This characteristic ensures the ideal scaffolding of the vessel, leading to enhanced blood flow and a decreased risk of re-narrowing or restenosis. In addition, these stents are suitable for application in intricate anatomical locations, enabling effective treatment even in challenging cases.

Moreover, the shift towards minimally invasive procedures has significantly contributed to the segment growth. In March 2025, BrosMed Medical Co. announced that it had received U.S. FDA 510(k) clearance for its Parafleet SC PTA Balloon Dilatation Catheters, including Parafleet SC 014, SC 018, and SC 035 models, designed for the treatment of symptomatic peripheral artery disease (PAD) and restoration of vessel patency in multiple peripheral vessels.

The self-expanding stents segment is expected to experience substantial growth in the market over the forecast period. The self-expanding stents are designed with materials such as nitinol, which have shape memory properties and can expand to fit the vessel walls. This flexibility allows the stent to conform to challenging lesions or narrow arteries, providing effective support and restoration of blood flow. Moreover, advancements in stent technologies, including improved stent designs and materials, contribute to the growth of the market. Self-expanding stents, in particular, offer advantages such as better flexibility, conformability, and reduced risk of recoil or collapse after deployment.

Product Insights

Based on product, the Iliac artery stents segment accounted for the largest share of 33.0% in 2025. Iliac artery stents are specialized medical devices designed to treat blockages or narrowing in the iliac arteries, which are the blood vessels located in the pelvis that supply blood to the lower extremities. Iliac arterial occlusive disease has a considerable impact, affecting approximately 8 million individuals in the U.S. alone.

These stents are typically made of metal or polymer materials and are inserted into the affected artery to help restore proper blood flow and prevent complications such as PAD or limb ischemia. For instance, in December 2025, the U.S. FDA approved additional implant sizes for Atrium Medical Corporation’s iCast Covered Stent System, which expands treatment options for patients with iliac artery occlusive disease.

The carotid artery stent segment is also expected to grow significantly over the forecast period. The growth of the carotid artery stent segment is due to the increasing prevalence of carotid artery disease (CAD), primarily caused by atherosclerosis. Atherosclerosis is the buildup of plaque within the arteries, leading to narrowing and decreased blood flow. According to reports from the Centers for Disease Control and Prevention (CDC), CAD is the most prevalent heart condition and a leading cause of mortality in the U.S. It is responsible for claiming the lives of over 370,000 individuals annually.

End-use Insights

Based on end-use, the hospital & cardiac centers segment accounted for the largest share of 74.5% in 2025. The rising prevalence of CVDs and the growing geriatric population. In addition, the increasing popularity of minimally invasive procedures further contributes to the market's growth and development. According to the WHO, CVDs are the leading cause of death worldwide, claiming an estimated 17.9 million lives each year. CVDs encompass a range of conditions that affect the heart and blood vessels, including coronary artery disease, heart attacks, stroke, and peripheral arterial disease. Moreover, hospital & cardiac centers are specialized medical facilities that play a crucial role in diagnosing and treating CVDs, including conditions related to PAD.

To learn more about this report, Download Free Sample Report

The ambulatory care centers segment is expected to experience substantial growth in the market over the forecast period. Ambulatory care centers have become a driving factor in the adoption and utilization of peripheral vascular stents. These centers provide an efficient and cost-effective alternative to traditional hospital settings for a wide range of outpatient procedures, including the placement of peripheral vascular stents.

Regional Insights

North America accounted for the largest share of 43.0% in 2025. North America has a well-established healthcare infrastructure, including advanced medical facilities and skilled healthcare professionals. This infrastructure supports the diagnosis and treatment of CVDs, making peripheral vascular stents readily available to patients in the region. Furthermore, the presence of key market players and technological advancements in the field of peripheral vascular stents has contributed to the market's growth in North America. Many leading medical device companies are headquartered or have a significant presence in the region, facilitating the development and commercialization of innovative stent technologies.

To learn more about this report, Download Free Sample Report

Asia Pacific Peripheral Vascular Stents Market Trends

The Asia Pacific region is expected to witness significant growth during the forecast period. This growth can be attributed to various factors such as sedentary lifestyles, unhealthy dietary habits, and an aging population contributing to the increased incidence of conditions like PAD. As a result, there is a growing demand for effective treatment options like peripheral vascular stents. In addition, rising government initiatives and supportive policies in the region, including public awareness campaigns, disease prevention programs, and favorable reimbursement policies, drive the growth of the peripheral vascular stents industry by promoting cardiovascular health and encouraging the adoption of advanced medical devices.

Key Peripheral Vascular Stents Company Insights

Key players are introducing advanced products at affordable prices to increase their market share and implementing strategic initiatives, such as acquisitions, mergers, and collaborations, to maximize their market dominance. For instance, in February 2025, Teleflex announced the acquisition of Vascular Intervention business of BIOTRONIK.

Key Peripheral Vascular Stents Companies

The following key companies have been profiled for this study on the peripheral vascular stents market:

• Boston Scientific Corporation

• Medtronic                

• Terumo Medical Corporation

• Abbott           

• Biotronik                  

• LifeTech Scientific Corporation                    

• iVascular S.L.U.

• Stryker                      

• Cook

• Microport Scientific Corporation             

• Stentys S.A.

• HELLMAN & FRIEDMAN LLC (Cordis Inc.)   

Recent Developments 

• In May 2025, Reflow Medical, Inc., one of the medical device developers, offering an extensive portfolio of devices for cardiovascular disease, announced that its Spur Peripheral Retrievable Stent System has received De Novo clearance from the U.S. FDA.

• In October 2025, Getinge, a Swedish medical technology company, announced its Advanta V12 Covered Stent System received the CE Mark approval as a bridging stent in fenestrated endovascular aneurysm repair (FEVAR), iliac branch device (IBD) aneurysmal repair, and branched endovascular aneurysm repair (BEVAR).

Global Peripheral Vascular Stents Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global peripheral vascular stents market report based on type, mode of delivery, product, end-use, and region.

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Drug Eluting Stents (DES)

  • Bare Metal Stents (BMS)

  • Bioabsorbable Stents

• Mode of Delivery Outlook (Revenue, USD Million, 2021 - 2033)

  • Self-expanding Stents

  • Balloon-expandable Stents

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Iliac Artery Stents

  • Femoral Artery Stents

  • Carotid Artery Stents

  • Renal Artery Stents

  • Other Peripheral Stents

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals & Cardiac Centers

  • Ambulatory Surgical Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait